source
- City Therapeutics raises $200 million in IPO, becoming 26th biotech listing of 2026City Therapeutics announced that it has completed a $200 million initial public offering, making it the 26th biotech to go public in 2026. The company, based in Kendall Square, will begin trading…
- Nouscom secures €120M to advance off-the-shelf cancer vaccine for Lynch syndromeSwiss biotech Nouscom announced a €120 million (about $135 million) Series D financing round. The capital will fund a registration-enabling pivotal trial of its cancer-preventing vaccine candidate.…